<SEC-DOCUMENT>0001161697-19-000189.txt : 20190508
<SEC-HEADER>0001161697-19-000189.hdr.sgml : 20190508
<ACCEPTANCE-DATETIME>20190508090042
ACCESSION NUMBER:		0001161697-19-000189
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20190507
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190508
DATE AS OF CHANGE:		20190508

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			REPRO MED SYSTEMS INC
		CENTRAL INDEX KEY:			0000704440
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				133044880
		STATE OF INCORPORATION:			NY
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-12305
		FILM NUMBER:		19805346

	BUSINESS ADDRESS:	
		STREET 1:		24 CARPENTER RD
		CITY:			CHESTER
		STATE:			NY
		ZIP:			10918
		BUSINESS PHONE:		845-469-2042

	MAIL ADDRESS:	
		STREET 1:		24 CARPENTER RD
		CITY:			CHESTER
		STATE:			NY
		ZIP:			10918
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form_8-k.htm
<DESCRIPTION>FORM 8-K CURRENT REPORT FOR 05-07-2019
<TEXT>
<HTML>
<HEAD>
</HEAD>
<TITLE></TITLE>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">
<DIV style="width:720px">
<BR>
<P style="margin:0" align=center><B>UNITED STATES</B></P>
<P style="margin:0" align=center><B>SECURITIES AND EXCHANGE COMMISSION</B></P>
<P style="margin:0" align=center><B>Washington, DC 20549</B></P>
<P style="margin:0" align=center>&nbsp;</P>
<P style="margin:0; font-size:12pt" align=center><B>FORM 8-K</B></P>
<P style="margin:0" align=center>&nbsp;</P>
<P style="margin:0; font-size:12pt" align=center><B>CURRENT REPORT</B></P>
<P style="margin:0; font-size:12pt" align=center><B>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</B></P>
<P style="margin:0" align=center>&nbsp;</P>
<P style="margin:0" align=center>Date of Report (Date of earliest event reported)&nbsp;&nbsp;&nbsp;<B><U>May 7, 2019</U></B></P>
<P style="margin:0" align=center>&nbsp;</P>
<P style="margin:0; font-size:14pt" align=center><B><U>REPRO MED SYSTEMS, INC.</U></B></P>
<P style="margin:0" align=center>(Exact name of registrant as specified in its charter)</P>
<P style="margin:0" align=center>&nbsp;</P>
<TABLE style="margin-top:0; font-size:10pt" cellpadding=0 cellspacing=0 align=center>
<TR><TD style="margin-top:0" valign=top width=240><P style="margin:0" align=center><B><U>New York</U></B></P>
</TD><TD style="margin-top:0" valign=top width=240><P style="margin:0" align=center><B><U>0-12305</U></B></P>
</TD><TD style="margin-top:0" valign=top width=240><P style="margin:0" align=center><B><U>13-3044880</U></B></P>
</TD></TR>
<TR><TD style="margin-top:0" valign=top width=240><P style="margin:0" align=center>(State or other jurisdiction<BR>
of incorporation)</P>
</TD><TD style="margin-top:0" valign=top width=240><P style="margin:0" align=center>(Commission<BR>
File Number)</P>
</TD><TD style="margin-top:0" valign=top width=240><P style="margin:0" align=center>(IRS Employer<BR>
Identification No.)</P>
</TD></TR>
</TABLE>
<P style="margin:0" align=center><BR></P>
<TABLE style="margin-top:0; font-size:10pt" cellpadding=0 cellspacing=0 align=center>
<TR><TD style="margin-top:0" valign=top width=288><P style="margin:0" align=center><B><U>24 Carpenter Road, Chester, New York</U></B></P>
</TD><TD style="margin-top:0" valign=top width=96><P style="margin:0" align=center><B><U>10918</U></B></P>
</TD></TR>
<TR><TD style="margin-top:0" valign=top width=288><P style="margin:0" align=center>(Address of principal executive offices)</P>
</TD><TD style="margin-top:0" valign=top width=96><P style="margin:0" align=center>(Zip Code)</P>
</TD></TR>
</TABLE>
<P style="margin:0" align=center><BR></P>
<P style="margin:0" align=center>Registrant&rsquo;s telephone number, including area code&nbsp;&nbsp;&nbsp;<B><U>(845) 469-2042</U></B></P>
<P style="margin:0" align=center>&nbsp;</P>
<P style="margin:0" align=center><U>not applicable</U></P>
<P style="margin:0" align=center>(Former name or former address, if changed since last report)</P>
<P style="margin:0" align=center>&nbsp;</P>
<P style="margin:0; text-align: justify">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</P>
<P style="margin:0; text-align: justify">&nbsp;</P>
<P style="margin:0; text-align: justify">[ &nbsp;] &nbsp;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</P>
<P style="margin:0; text-align: justify">&nbsp;</P>
<P style="margin:0; text-align: justify">[ &nbsp;] &nbsp;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</P>
<P style="margin:0; text-align: justify">&nbsp;</P>
<P style="margin:0; text-align: justify">[ &nbsp;] &nbsp;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</P>
<P style="margin:0; text-align: justify">&nbsp;</P>
<P style="margin:0; text-align: justify">[ &nbsp;] &nbsp;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</P>
<P style="margin:0; text-align: justify">&nbsp;</P>
<P style="margin:0; text-align: justify">Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>
<P style="margin:0; text-align: justify">&nbsp;</P>
<P style="margin:0; text-align: justify">Emerging growth company &nbsp;[_]</P>
<P style="margin:0; text-align: justify">&nbsp;</P>
<P style="margin:0; text-align: justify">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &nbsp;[_]</P>
<P style="margin:0; text-align: justify">&nbsp;</P>
<P style="margin:0; text-align: justify">Securities registered pursuant to Section 12(b) of the Act:</P>
<P style="margin:0; text-align: justify">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="margin-top: 0px; font-size: 10pt"><TR height=0 style="font-size:1pt"><TD STYLE="width: 2.5in"></TD><TD STYLE="width: 2.5in"></TD><TD STYLE="width: 2.5in"></TD></TR>
<TR><TD STYLE="margin-top: 0px; vertical-align: top"><P style="margin:0px"><U>Title of each class</U></P>
</TD><TD STYLE="margin-top: 0px; vertical-align: top"><P style="margin:0px"><U>Trading symbol(s)</U></P>
</TD><TD STYLE="margin-top: 0px; vertical-align: top"><P style="margin:0px"><U>Name of each exchange on which registered</U></P>
</TD></TR>
<TR><TD STYLE="margin-top: 0px; vertical-align: top"><P style="margin:0px">common stock, $0.01 par value </P>
</TD><TD STYLE="margin-top: 0px; vertical-align: top"><P style="margin:0px">REPR</P>
</TD><TD STYLE="margin-top: 0px; vertical-align: top"><P style="margin:0px">OTCQX</P>
</TD></TR>
</TABLE>
<P style="margin:0; text-align: justify">&nbsp;</P>

<HR noshade align="center" width="100%" size="2"><p style='page-break-before:always'></p><PAGE><BR>

<P style="margin:0px; text-align: justify"><B>ITEM 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.</B></P>
<P style="margin:0px; text-align: justify"><BR></P>
<P style="margin:0px; text-align: justify"><B>(d) &nbsp;Election of Directors</B></P>
<P style="margin:0px; text-align: justify"><BR></P>
<P style="margin:0px; text-align: justify">On May 7, 2019, R. John Fletcher was appointed to the Board of Directors (the &ldquo;Board&rdquo;) of Repro
Med Systems, Inc. (the &ldquo;Company&rdquo;), filling a vacancy on the board resulting from the death of Arthur J. Radin.</P>
<P style="margin:0px; text-align: justify"><BR></P>
<P style="margin:0px; text-align: justify">Mr. Fletcher brings more than 35 years of healthcare and medical device experience to RMS Medical. He currently
serves as CEO and Managing Director of Fletcher Spaght Inc., a strategy consulting and venture capital firm which he founded in
1983. Prior to founding Fletcher Spaght, he was Senior Manager at The Boston Consulting Group, advising a broad range of companies
in healthcare and high technology industries.</P>
<P style="margin:0px; text-align: justify"><BR></P>
<P style="margin:0px; text-align: justify">Mr. Fletcher joined the Board of Directors of publicly-traded medical device company Spectranetics Corporation
in 2002 and served as Chairman of the Board from 2010-2017. Mr. Fletcher was named 2018 Director of the Year by The National Association
of Corporate Directors (NACD) for his work at Spectranetics.</P>
<P style="margin:0px; text-align: justify"><BR></P>
<P style="margin:0px; text-align: justify">Mr. Fletcher currently serves on the Board of Directors of Axcelis Corporation, MRI Interventions and is Chairman
of Metabolon. He is Chairman Emeritus of the Corporate Collaboration Council at the Thayer School of Engineering/Tuck School of
Business at Dartmouth College and serves on the Board of Advisors of Beth Israel Deaconess Medical Center and the Whitehead Institute
at MIT. Mr. Fletcher received his MBA from Southern Illinois University and a BBA in Marketing from George Washington University.
He was an Instructor for courses in international business and a Ph.D. Candidate at the Wharton School of the University of Pennsylvania.
Mr. Fletcher served as a Captain and jet pilot in the United States Air Force.</P>
<P style="margin:0px; text-align: justify"><BR></P>
<P style="margin:0px; text-align: justify">Mr. Fletcher has been appointed as a member of the Board&rsquo;s Audit Committee. There are no family relationships
between Mr. Fletcher and any director or other executive officer of the Company nor are there any transactions between Mr. Fletcher
or any member of his immediate family and the Company that would be reportable as a related party transaction under the rules of
the United States Securities and Exchange Commission. Further, there is no arrangement or understanding between Mr. Fletcher and
any other persons or entities pursuant to which Mr. Fletcher was appointed as a director of the Company.</P>
<P style="margin:0px; text-align: justify"><BR></P>
<P style="margin:0px; text-align: justify">Upon his appointment to the Board, Mr. Fletcher became entitled to a pro-rated portion of the Company&rsquo;s non-employee
director compensation. As such, Mr. Fletcher is entitled to receive a prorated portion of the annual director retainer of $50,000
paid half in cash and half in shares of the Company&rsquo;s common stock. Mr. Fletcher will also be entitled to receive reimbursement
of his reasonable travel expenses incurred in connection with his attendance at Board and committee meetings.</P>
<P style="margin:0px; text-align: justify"><BR></P>
<P style="margin:0"><B>ITEM 8.01 OTHER EVENTS.</B></P>
<P style="margin:0px; text-align: justify"><BR></P>
<P style="margin:0px; text-align: justify"><B>Appointment of Chairman of Audit Committee</B></P>
<P style="margin:0px; text-align: justify"><BR></P>
<P style="margin:0px; text-align: justify">On May 7, 2019, the Board appointed David W. Anderson, a current Company director, as Chairman of the Audit
Committee.</P>
<P style="margin:0px; text-align: justify"><BR></P>
<P style="margin:0px; text-align: justify">On May 8, 2019, the Company issued a press release announcing the events set forth in this Current Report
on Form 8-K. A copy of the press release is furnished as Exhibit 99.1 hereto.</P>
<P style="margin:0px; text-align: justify"><BR></P>
<P style="margin:0"><B>ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.</B></P>
<P style="margin:0px; text-align: justify"><BR></P>
<P style="margin:0; text-align: justify">(d) Exhibits.</P>
<P style="margin:0px; text-align: justify"><BR></P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 720px">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 96"><U>Exhibit No.</U></TD>
    <TD STYLE="width: 624"><U>Description</U></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>99.1</TD>
    <TD><A HREF="ex_99-1.htm">Press release dated May 8, 2019</A></TD></TR>
</TABLE>
<P style="margin:0px; text-align: justify"><BR></P>
<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">- 2 -</P>

<HR noshade align="center" width="100%" size="2"><p style='page-break-before:always'></p><PAGE><BR>

<P style="margin:0" align=center><B>SIGNATURES</B></P>
<P style="margin:0px; text-align: justify"><BR></P>
<P style="margin:0; text-indent:48; text-align: justify">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>
<P style="margin:0px; text-align: justify"><BR></P>
<TABLE style="margin-top:0; font-size:10pt" cellpadding=0 cellspacing=0 width=100%>
<TR><TD style="margin-top:0" valign=top><P style="margin:0">&nbsp;</P>
</TD><TD style="margin-top:0" valign=top width=360 colspan=2><P style="margin:0">REPRO MED SYSTEMS, INC.<BR>
(Registrant)</P>
</TD></TR>
<TR><TD style="margin-top:0" valign=top><P style="margin:0">&nbsp;</P>
</TD><TD style="margin-top:0" valign=top width=24><P style="margin:0">&nbsp;</P>
</TD><TD style="margin-top:0" valign=top width=336><P style="margin:0">&nbsp;</P>
</TD></TR>
<TR><TD style="margin-top:0" valign=top><P style="margin:0">Date: &nbsp;<U>May 8, 2019</U></P>
</TD><TD style="margin-top:0" valign=top width=24><P style="margin:0">By:</P>
</TD><TD style="margin-top:0" valign=top width=336><P style="margin:0"><U>/s/ Donald B. Pettigrew</U></P>
</TD></TR>
<TR><TD style="margin-top:0" valign=top colspan=2><P style="margin:0">&nbsp;</P>
</TD><TD style="margin-top:0" valign=top width=336><P style="margin:0">Donald B. Pettigrew<BR>
President and Chief Executive Officer</P>
</TD></TR>
</TABLE>
<P style="margin:0"><BR></P>
<P style="margin:0" align=center>- 3 -</P>
<HR noshade align="center" width="100%" size="2">
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>ex_99-1.htm
<DESCRIPTION>PRESS RELEASE DATED MAY 8, 2019
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 12pt Times New Roman, Times, Serif">
<DIV style="width:720px">
<BR>
<P style="margin:0px" align=center><B>Exhibit 99.1</B></P>

<P style="margin:0px">&nbsp;</P>

<P style="margin:0px"><img src="rms_logo.jpg"></P>

<P style="margin:0px">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>RMS MEDICAL PRODUCTS APPOINTS HEALTHCARE
INDUSTRY VETERAN</U></B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>R. JOHN FLETCHER TO BOARD OF DIRECTORS</U></B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>Former Chairman of Spectranetics Corporation;
NACD 2018 Director of the Year</U></B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>CHESTER, NY &ndash; May 8, 2019 - Repro
Med Systems, Inc. dba RMS Medical Products (OTCQX: REPR) (&ldquo;RMS Medical&rdquo;) </B>today announced that
R. John Fletcher has been appointed as an independent member of RMS Medical&rsquo;s Board of Directors. With this appointment,
RMS Medical&rsquo;s Board of Directors fills the vacancy created by the passing of Arthur J. Radin.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Mr.
Fletcher brings more than 35 years of healthcare and medical device experience to RMS Medical. He currently serves as CEO
and Managing Director of Fletcher Spaght Inc., a strategy consulting and venture capital firm which he founded in 1983. Prior to
founding Fletcher Spaght, he was Senior Manager at The Boston Consulting Group, advising a broad range of companies in healthcare
and high technology industries.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Mr. Fletcher joined
the Board of Directors of publicly-traded medical device company Spectranetics Corporation in 2002 and served as Chairman of the
Board from 2010-2017. During his 15-year tenure as a member of the board, Spectranetics expanded
its therapeutic platforms and generated significant commercial growth. In August 2017 Spectranetics was acquired by Royal Philips
in a transaction valued at $2.2 billion. Mr. Fletcher was named 2018 Director of the Year by The National Association of Corporate
Directors (NACD) for his work at Spectranetics.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Mr. Fletcher currently
serves on the Board of Directors of Axcelis Corporation, MRI Interventions and is Chairman of Metabolon. He is Chairman Emeritus
of the Corporate Collaboration Council at the Thayer School of Engineering/Tuck School of Business at Dartmouth College and serves
on the Board of Advisors of Beth Israel Deaconess Medical Center and the Whitehead Institute at MIT. Mr. Fletcher received his
MBA from Southern Illinois University and a BBA in Marketing from George Washington University. He was an Instructor for courses
in international business and a Ph.D. Candidate at the Wharton School of the University of Pennsylvania. Mr. Fletcher served as
a Captain and jet pilot in the United States Air Force.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&ldquo;John&rsquo;s vision and leadership in
the medical device industry has helped improve the lives of patients around the world,&rdquo; said Don Pettigrew, President and
CEO of RMS Medical. &ldquo;We believe he will be a significant asset as we continue to expand RMS Medical&rsquo;s business and
elevate our industry profile.&rdquo;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&ldquo;John is an
industry veteran and brings to RMS Medical a proven record of building brands, teams and businesses, and advising growth-oriented
public companies in the healthcare industry,&rdquo; said Daniel S. Goldberger, Executive Chairman of RMS Medical. &ldquo;I am thrilled
and excited to welcome him to our board.&rdquo;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: -0.3pt; background-color: white">&ldquo;It&rsquo;s
an exciting time at RMS Medical and I am very pleased to join the Board of Directors,&rdquo; said Mr. Fletcher. &ldquo;The infusion
therapy market is growing and I believe RMS Medical, with its portfolio of reliable, easy-to-use, and effective products, is well-positioned
to participate in this anticipated industry growth.&rdquo;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<HR noshade align="center" width="100%" size="2"><p style='page-break-before:always'></p><PAGE><BR>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><U>David W. Anderson Named Audit Committee
Chair</U></B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">RMS Medical also announced that David W. Anderson
has been appointed Chairman of the Audit Committee. Mr. Anderson succeeds Arthur J. Radin. A member of the Board of Directors since
2016, Mr. Anderson is a seasoned healthcare executive with more than 23 years of experience in the medical device industry.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&ldquo;David is a valued board member with
a distinguished background in the healthcare industry, and we welcome him to his new position,&rdquo; said Mr. Goldberger.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">John Fletcher will join the Audit Committee
with David Anderson and Robert Allen.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><U>About RMS Medical Products</U></B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">RMS Medical develops, manufactures and commercializes
innovative and easy-to-use specialty infusion solutions that improve quality of life for patients around the world. The FREEDOM
Syringe Infusion System currently includes the FREEDOM60<SUP>&reg;</SUP> and FreedomEdge<SUP>&reg;</SUP> Syringe Infusion Drivers,
RMS Precision Flow Rate Tubing<SUP>&trade;</SUP> and RMS HIgH-Flo Subcutaneous Safety Needle Sets<SUP>&trade;</SUP>. These devices
are used for infusions administered in the home and alternate care settings. For more information about RMS Medical, please visit
www.rmsmedicalproducts.com.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><U>Forward-Looking Statements</U></B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The statements contained herein include prospects,
statements of future expectations and other forward-looking statements within the meaning of the Private Securities Litigation
Reform Act of 1995 that are based on management&rsquo;s current views and assumptions and involve known and unknown risks and uncertainties,
identified by words such as &ldquo;believe&rdquo; and &ldquo;will&rdquo;. Actual results, performance or events may differ materially from
those expressed or implied in such forward-looking statements. Factors that may cause actual results to differ materially from
current expectations and other risks are discussed in RMS Medical&rsquo;s filings with the U.S. Securities and Exchange Commission,
including its Annual Report on Form 10-K, which filings are available from the SEC and RMS Medical&rsquo;s website. RMS Medical
undertakes no obligation to update any forward-looking statements.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><B>Contacts:</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 179.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>The Equity Group Inc.</B></FONT></TD>
    <TD STYLE="width: 180.9pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">Devin Sullivan</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">Kalle Ahl, CFA</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">Senior Vice President</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">Vice President</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">212-836-9608</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">212-836-9614</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">mailto:dsullivan@equityny.com</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">kahl@equityny.com </FONT></TD></TR>
</TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">- 2 -</P>

<HR noshade align="center" width="100%" size="2">
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>rms_logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 rms_logo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  P *H# 2(  A$! Q$!_\0
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MQ/\ LJ_&Z:8.=Y8/!>_"GXP7&F619XV_X1OXA,VC9)^)'P]T6,ZO]7?M??\
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M'5?#3>'M<TG5FU.]T30I;-I+^TN;,#3_ +7<_P 9WQ=_X(S?'WX$?L"_'O\
M;S_:[\6ZCX9^*5A/\+=1\*?!U]2C\7>-[[5OBM\<OAQX$UWQ?\>/'=]<ZOO\
M07&E>,=<U!?">BWVJZTFNS6&K>*?&%I>VNL^$+C]8O\ @D%X8\6>./\ @@C_
M ,%!O!/@*QO]3\<>+V_;4\,>$-,TI9)-5U3Q+KO[,_@[2]&TW2TA(E.I:A?W
M,%E8"%UE^USPF)T<!AZW$?AWX>8+@&./R+/*F>9Q@^.,BX4S?BJ$Z]#*(SS*
MI0IYE# 8626'J9;@:.*ABH8EU:E><\-4G5Q4XQE3,,)FN;5<T6'Q>'AA*-3
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M<(Q@^*AFN.Q5%5ZV?Y=@9U93DL)4PJA5H14Y*,*LI-N;T34DM5K+WG)'@/\
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?2V2N[1C=+W8JRCOI]J2LSJO?K?HGY+17OUTU\S__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
